{"id":55111,"date":"2023-03-22T23:03:20","date_gmt":"2023-03-22T22:03:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/"},"modified":"2023-03-22T23:03:20","modified_gmt":"2023-03-22T22:03:20","slug":"morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/","title":{"rendered":"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President"},"content":{"rendered":"
\n

SEATTLE–(BUSINESS WIRE)–Morphimmune, Inc., a preclinical biotechnology company focused on developing targeted oncology therapeutics, today announced the appointment of Clay Siegall, Ph.D. as its CEO and President.\n<\/p>\n

\n\u201cClay is a highly passionate and effective leader with a demonstrated ability to build significant value for an emerging biotechnology company,\u201d said Isaac Barchas, Morphimmune\u2019s Founding Board Chairman, co-founder and CEO of Research Bridge Partners, which made seed capital and follow-on investments in the company in 2020. \u201cHis emphasis on scientific and clinical excellence will drive Morphimmune\u2019s development of novel targeted therapeutics with the goal to deliver significant benefit to cancer patients.\u201d\n<\/p>\n

\n\u201cI am pleased to join Morphimmune as CEO,\u201d said Dr. Siegall. \u201cMorphimmune\u2019s targeted effector platform has the potential to deliver the next generation of oncology therapeutics. I look forward to advancing the company\u2019s pipeline into the clinic while expanding its technology suite.\u201d\n<\/p>\n

\n\u201cClay immediately understood the vision for Morphimmune and is the right leader to advance our goal of saving patient lives,\u201d said Dr. Philip Low, Morphimmune co-founder.\n<\/p>\n

\nDr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997. Under his nearly 25 years of leadership, Seagen became the world leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue. During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company\u2019s acquisition of Cascadian Therapeutics. Earlier this month, Pfizer, Inc. agreed to purchase Seagen for $43 billion.\n<\/p>\n

\nPrior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and the National Cancer Institute. He earned a Ph.D. in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.\n<\/p>\n

\nMorphimmune was founded on the research of the company\u2019s scientific co-founder Dr. Low, the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low previously founded Endocyte, which Novartis acquired for $2.1 billion in 2018. He has published more than 500 articles and has over 700 patents\/patents pending, in addition to being the founder of seven companies to commercialize these discoveries.\n<\/p>\n

\nAbout Morphimmune, Inc.<\/b>\n<\/p>\n

\nMorphimmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company\u2019s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases efficacy of known effector molecules, ultimately improving outcomes for patients. For more information, visit www.morphimmune.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor media inquiries, please contact media@morphimmune.com<\/a>.\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEATTLE–(BUSINESS WIRE)–Morphimmune, Inc., a preclinical biotechnology company focused on developing targeted oncology therapeutics, today announced the appointment of Clay Siegall, Ph.D. as its CEO and President. \u201cClay is a highly passionate and effective leader with a demonstrated ability to build significant value for an emerging biotechnology company,\u201d said Isaac Barchas, Morphimmune\u2019s Founding Board Chairman, co-founder … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55111","6":"format-standard","7":"category-industry"},"yoast_head":"\nMorphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEATTLE–(BUSINESS WIRE)–Morphimmune, Inc., a preclinical biotechnology company focused on developing targeted oncology therapeutics, today announced the appointment of Clay Siegall, Ph.D. as its CEO and President. \u201cClay is a highly passionate and effective leader with a demonstrated ability to build significant value for an emerging biotechnology company,\u201d said Isaac Barchas, Morphimmune\u2019s Founding Board Chairman, co-founder ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-22T22:03:20+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President\",\"datePublished\":\"2023-03-22T22:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/\"},\"wordCount\":435,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/\",\"name\":\"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-22T22:03:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/","og_locale":"en_US","og_type":"article","og_title":"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President - Pharma Trend","og_description":"SEATTLE–(BUSINESS WIRE)–Morphimmune, Inc., a preclinical biotechnology company focused on developing targeted oncology therapeutics, today announced the appointment of Clay Siegall, Ph.D. as its CEO and President. \u201cClay is a highly passionate and effective leader with a demonstrated ability to build significant value for an emerging biotechnology company,\u201d said Isaac Barchas, Morphimmune\u2019s Founding Board Chairman, co-founder ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-22T22:03:20+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President","datePublished":"2023-03-22T22:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/"},"wordCount":435,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/","url":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/","name":"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-22T22:03:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/morphimmune-appoints-dr-clay-siegall-chief-executive-officer-and-president\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55111"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55111\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}